The Business Research Company’s report on the Neuromodulation Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the neuromodulation market’s growth in recent years?
The growing prevalence of neurological disorders is expected to propel the growth of the neuromodulation market going forward. Neurological disorders are technically defined as problems that affect the brain as well as the nerves located throughout the human body and the spinal cord. Neuromodulation offers the ability to cure and modulate a wide range of neurological disorders and diseases, such as Parkinson’s and Alzheimer’s diseases. For instance, in April 2022, according to the European Brain Council, a Belgium-based coordinating international health organization, there were over 600 neurological diseases and nearly 300 psychiatric conditions noted. Worldwide, there were 50 million people living with Alzheimer’s and other dementias. Epilepsy is common disorder that affected 65 million people around the world. In Europe, 10.5 million people had dementia, which is expected to increase to 18.7 million in 2050. Thus, the growing prevalence of neurological disorders is driving the growth of the neuromodulation market.
Access Your Free Sample of the Global Neuromodulation Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10142&type=smp
How does the future projection of the neuromodulation market size compare to its historical growth?
The neuromodulation market size has grown rapidly in recent years. It will grow from$6.96 billion in 2024 to $7.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising prevalence of chronic disorders, clinical evidence and research, patient demand for non-invasive therapies, government initiatives and funding, expansion of indications, collaborations and partnerships
The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to “$11.79 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to miniaturization of devices, focus on neurological disorders in aging population, expanded applications in psychiatry, patient-centric approaches, global expansion of healthcare access. Major trends in the forecast period include integration of artificial intelligence (ai), advancements in technology, non-invasive neuromodulation techniques, closed-loop neuromodulation systems, expansion of indications, wireless and wearable neuromodulation devices.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10142&type=smp
Which key players are shaping the future of the neuromodulation market?
Major companies operating in the neuromodulation market include Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, Neuropace Inc., LivaNova PLC, Neurosigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, ReShape Lifesciences Inc., Inspire Medical Systems Inc., Bioventus LLC, Saluda Medical Pty Ltd, Otolith Labs Inc., Machine Medicine Inc., Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuronoff ApS, Neuros Medical Inc., Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., Magic Leap Inc., Omron Corporation
What trends will propel the growth and evolution of the neuromodulation market?
Technological advancements are a key trend gaining popularity in the neuromodulation market. Major companies operating in the neuromodulation market are focused on developing new technological solutions to strengthen their position in the market. For example, in January 2024, GrayMatters Health, an Israel-based company specializing in digital self-neuromodulation therapies, launched a new FDA-cleared self-neuromodulation therapy for PTSD called Prism. This innovative device combines an EEG cap with software to help patients learn to control their emotional responses through neurofeedback. The technology is designed to augment standard psychotherapy and pharmacotherapy, providing patients with tools to manage their symptoms actively. Further, in December 2022, Abbott Laboratories, a US-based medical devices and healthcare company, launched the Eterna spinal cord stimulation (SCS) system, the smallest implantable, rechargeable spinal cord stimulator. Eterna SCS employs Abbott’s patented low-dose BurstDR stimulation, the only SCS waveform innovation with the highest level of clinical proof (1A evidence), which has been shown to relieve pain by 23% more than typical waveform technology approaches.
Which regions are expected to become dominant players in the neuromodulation market?
North America was the largest region in the neuromodulation market in 2024. The regions covered in the neuromodulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/neuromodulation-global-market-report
What are the emerging key segments in the neuromodulation market, and how are they evolving?
The neuromodulation market covered in this report is segmented –
1) By Technology: Internal Neuromodulation, External Neuromodulation (Non-invasive)
2) By Biomaterial: Polymeric Biomaterial, Metallic Biomaterial, Ceramic Biomaterial
3) By Application: Chronic Pain, Urinary And Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, Other Applications
4) By End-User: Hospitals, Clinics, Home Healthcare
Subsegments:
1) By Internal Neuromodulation: Implantable Devices, Intrathecal Drug Delivery Systems
2) By External Neuromodulation (Non-invasive): Transcranial Magnetic Stimulation (TMS), Transcranial Direct Current Stimulation (tDCS), Transcutaneous Electrical Nerve Stimulation (TENS), Peripheral Nerve Stimulation (PNS)
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10142
What defines the structure and scope of the neuromodulation market?
Neuromodulation is the modification of nerve activity (or modulation) by delivering electrical or pharmacological substances directly to a specific location. It is a reversible procedure performed to relieve pain.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
